Results 51 to 60 of about 104,116 (405)

Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine‐maintained heroin users [PDF]

Addiction Biology, 2014
AbstractIn spite of the clinical utility of buprenorphine, parenteral abuse of this medication has been reported in several laboratory investigations and in the real world. Studies have demonstrated lower abuse liability of the buprenorphine/naloxone combination relative to buprenorphine alone.
Verena E. Metz, Shanthi Mogali, Suzanne K. Vosburg, Jeanne M. Manubay, Jermaine D. Jones, Maria A. Sullivan, Sandra D. Comer   +6 more
openaire   +2 more sources

Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel

Regional anesthesia and pain medicine, 2021
Background The past two decades have witnessed an epidemic of opioid use disorder (OUD) in the USA, resulting in catastrophic loss of life secondary to opioid overdoses.
L. Kohan, Sudheer Potru, Antje M. Barreveld, M. Sprintz, Olabisi Lane, Anuj Aryal, T. Emerick, A. Dopp, Sophia Chhay, E. Viscusi   +9 more
semanticscholar   +1 more source

Buprenorphine is a weak dopamine releaser relative to heroin, but its pretreatment attenuates heroin‐evoked dopamine release in rats

Neuropsychopharmacology Reports, 2020
Aims The United States of America is currently in an opioid epidemic. Heroin remains the most lethal opioid option with its death rate increasing by over 500% in the last decade.
Dominic P. Isaacs, Ryan P. Leman, Thomas J. Everett, Hendrick Lopez‐Beltran, Lindsey R. Hamilton, Erik B. Oleson   +5 more
doaj   +1 more source

Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-Based Setting [PDF]

, 2007
CONTEXT Although office-based opioid treatment with buprenorphine (OBOT-B) has been successfully implemented in primary care settings in the US, its use has not been reported in homeless patients.
Alford, Daniel P., Cheng, Debbie M., Hohl, Carole A., LaBelle, Colleen T., O'Connell, James J., Richardson, Jessica M., Samet, Jeffrey H.   +6 more
core   +3 more sources

Assessment of immunotoxicity of buprenorphine [PDF]

Laboratory Animals, 1994
In order to use buprenorphine as an analgesic in immunological experiments, we have studied the potential immunotoxicity of buprenorphine. Three-week-old male Wistar Riv: TOX rats were subcutaneously treated with buprenorphine by injection of 0.1, 0.4, or 1.6 mg/kg body weight per day over a period of 4 weeks. Concentrations used were within the range
van Loveren, H, Gianotten, N, Hendriksen, CFM, Schuurman, HJ, van der Laan, JW   +4 more
openaire   +3 more sources

Community pharmacy attitudes and behaviors following a buprenorphine best practices dissemination [PDF]

Mental Health Clinician
Introduction: Opioid overdose deaths continue to rise despite available safe and efficacious treatments for opioid use disorder, such as buprenorphine. Whereas provider-level access to buprenorphine has improved, community pharmacy-level barriers remain,
Winter Roth, PharmD, BCPP, David Dadiomov, PharmD, BCPP   +1 more
doaj   +1 more source

Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats [PDF]

, 2017
The aim of this study was to describe the joint pharmacokinetic-pharmacodynamic model and evaluate thermal antinociception of a high-concentration formulation of buprenorphine (Simbadol™) in ...
Beaudry, F, Benito, J, Doodnaught, G M, Edge, D, Monteiro, B P, Pelligand, L, Steagall, P   +6 more
core   +3 more sources

A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic

Journal of addiction medicine, 2021
Objectives: The purpose of this study was to assess the feasibility and clinical impact of telemedicine-based opioid treatment with buprenorphine-naloxone following the Coronavirus disease 2019 pandemic.
B. Tofighi, J. McNeely, Dalia Walzer, Kush Fansiwala, Adam Demner, Chloe S Chaudhury, Ipsita Subudhi, Daniel Schatz, Timothy Reed, N. Krawczyk   +9 more
semanticscholar   +1 more source

Barriers and Facilitators to Clinician Readiness to Provide Emergency Department–Initiated Buprenorphine

JAMA Network Open, 2020
This qualitative analysis surveys barriers and facilitators of readiness to initiate buprenorphine administration in the emergency department and identifies opportunities to promote readiness among clinicians to treat patients with opioid use disorder.
Kathryn F. Hawk, G. D'Onofrio, M. Chawarski, P. O'Connor, E. Cowan, M. Lyons, L. Richardson, R. Rothman, L. Whiteside, P. Owens, Shara Martel, E. Coupet, M. Pantalon, L. Curry, D. Fiellin, E. Edelman   +15 more
semanticscholar   +1 more source

Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl

medRxiv, 2021
Background Induction of buprenorphine, an evidence-based treatment for opioid use disorder (OUD), has been reported to be difficult for people with heavy use of fentanyl, the most prevalent opioid in many areas of the country.
A. Spadaro, Abeed Sarker, W. Hogg-Bremer, Jennifer S Love, Nicole O’Donnell, Lewis S. Nelson, Jeanmarie Perrone   +6 more
semanticscholar   +1 more source